Association of IL1RAP-related Genetic Variation with Cerebrospinal Fluid Concentration of Alzheimer-associated Tau Protein

Overview

Journal Sci Rep

Specialty Science

Date 2019 Feb 23

PMID 30792413

Citations 7

Authors

Anna Zettergren

Kina Hoglund

Silke Kern

Valgeir Thorvaldsson

Msc Johan Skoog

Oskar Hansson

Niels Andreasen

Nenad Bogdanovic

Kaj Blennow

Ingmar Skoog

Henrik Zetterberg

Affiliations

Soon will be listed here.

Abstract

A possible involvement of the gene IL1RAP (interleukin-1 receptor-associated protein) in the pathogenesis of Alzheimer's disease (AD) has been suggested in GWASs of cerebrospinal fluid (CSF) tau levels and longitudinal change in brain amyloid burden. The aim of this study was to examine previously implicated genetic markers in and near IL1RAP in relation to AD risk, CSF tau and Aβ biomarkers, as well as cognitive decline, in a case (AD)-control study and an age homogenous population-based cohort. Genotyping of IL1RAP-related single nucleotide polymorphisms (SNPs), selected based on previous GWAS results, was performed. 3446 individuals (1154 AD cases and 2292 controls) were included in the analyses of AD risk, 1400 individuals (cognitively normal = 747, AD = 653) in the CSF biomarker analyses, and 861 individuals in the analyses of cognitive decline. We found no relation between IL1RAP-related SNPs and AD risk. However, CSF total-tau and phospho-tau were associated with the SNP rs9877502 (p = 6 × 10 and p = 5 × 10). Further, nominal associations (p = 0.03-0.05) were found between three other SNPs and CSF biomarker levels, or levels of cognitive performance and decline in a sub-sample from the general population. These results support previous studies suggesting an association of IL1RAP with disease intensity of AD.

Citing Articles

Pathway enrichment in genome-wide analysis of longitudinal Alzheimer's disease biomarker endophenotypes.

Rosewood T, Nho K, Risacher S, Liu S, Gao S, Shen L Alzheimers Dement. 2024; 20(12):8639-8650.

PMID: 39440837 PMC: 11667536. DOI: 10.1002/alz.14308.

Characterization of genomic regions escaping epigenetic reprogramming in sheep.

Braz C, Passamonti M, Khatib H Environ Epigenet. 2024; 10(1):dvad010.

PMID: 38496251 PMC: 10944287. DOI: 10.1093/eep/dvad010.

Cause or consequence? The role of IL-1 family cytokines and receptors in neuroinflammatory and neurodegenerative diseases.

Boraschi D, Italiani P, Migliorini P, Bossu P Front Immunol. 2023; 14:1128190.

PMID: 37223102 PMC: 10200871. DOI: 10.3389/fimmu.2023.1128190.

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.

Jansen I, van der Lee S, Gomez-Fonseca D, de Rojas I, Dalmasso M, Grenier-Boley B Acta Neuropathol. 2022; 144(5):821-842.

PMID: 36066633 PMC: 9547780. DOI: 10.1007/s00401-022-02454-z.

Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer's Disease Patients.

Gagliardi S, Truffi M, Tinelli V, Garofalo M, Pandini C, Ramusino M Int J Mol Sci. 2022; 23(16).

PMID: 36012501 PMC: 9409287. DOI: 10.3390/ijms23169237.

References

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B . Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999; 56(6):673-80. DOI: 10.1001/archneur.56.6.673. View

Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M . Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000; 285(1):49-52. DOI: 10.1016/s0304-3940(00)01036-3. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Haftenberger M, Schuit A, Tormo M, Boeing H, Wareham N, Bueno-de-Mesquita H . Physical activity of subjects aged 50-64 years involved in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr. 2003; 5(6B):1163-76. DOI: 10.1079/PHN2002397. View

Violato C, Hecker K . How to use structural equation modeling in medical education research: a brief guide. Teach Learn Med. 2007; 19(4):362-71. DOI: 10.1080/10401330701542685. View

Zetterberg M, Landgren S, Andersson M, Seibt Palmer M, Gustafson D, Skoog I . Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(6):720-6. DOI: 10.1002/ajmg.b.30668. View

Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C . Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res Rev. 2008; 59(1):155-63. DOI: 10.1016/j.brainresrev.2008.07.003. View

Blom E, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman B . Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord. 2009; 27(5):458-64. PMC: 7077080. DOI: 10.1159/000216841. View

Gabay C, Lamacchia C, Palmer G . IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010; 6(4):232-41. DOI: 10.1038/nrrheum.2010.4. View

10.

Weiner M, Aisen P, Jack Jr C, Jagust W, Trojanowski J, Shaw L . The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010; 6(3):202-11.e7. PMC: 2927112. DOI: 10.1016/j.jalz.2010.03.007. View

11.

Wang D, Zhang S, Li L, Liu X, Mei K, Wang X . Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol. 2010; 11(10):905-11. DOI: 10.1038/ni.1925. View

12.

Prinz M, Priller J, Sisodia S, Ransohoff R . Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci. 2011; 14(10):1227-35. DOI: 10.1038/nn.2923. View

13.

Kang H, Kawasawa Y, Cheng F, Zhu Y, Xu X, Li M . Spatio-temporal transcriptome of the human brain. Nature. 2011; 478(7370):483-9. PMC: 3566780. DOI: 10.1038/nature10523. View

14.

De Jager P, Shulman J, Chibnik L, Keenan B, Raj T, Wilson R . A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2011; 33(5):1017.e1-15. PMC: 3307898. DOI: 10.1016/j.neurobiolaging.2011.09.033. View

15.

Qin X, Peng Q, Zeng Z, Chen Z, Lin L, Deng Y . Interleukin-1A -889C/T polymorphism and risk of Alzheimer's disease: a meta-analysis based on 32 case-control studies. J Neurol. 2012; 259(8):1519-29. DOI: 10.1007/s00415-011-6381-6. View

16.

Bennett D, Schneider J, Arvanitakis Z, Wilson R . Overview and findings from the religious orders study. Curr Alzheimer Res. 2012; 9(6):628-45. PMC: 3409291. DOI: 10.2174/156720512801322573. View

17.

Payao S, Goncalves G, de Labio R, Horiguchi L, Mizumoto I, Rasmussen L . Association of interleukin 1β polymorphisms and haplotypes with Alzheimer's disease. J Neuroimmunol. 2012; 247(1-2):59-62. DOI: 10.1016/j.jneuroim.2012.03.012. View

18.

Hua Y, Zhao H, Kong Y, Lu X . Meta-analysis of the association between the interleukin-1A -889C/T polymorphism and Alzheimer's disease. J Neurosci Res. 2012; 90(9):1681-92. DOI: 10.1002/jnr.23062. View

19.

Lourdusamy A, Newhouse S, Lunnon K, Proitsi P, Powell J, Hodges A . Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet. 2012; 21(16):3719-26. PMC: 6446535. DOI: 10.1093/hmg/dds186. View

20.

Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K . Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2012; 33(1):45-53. DOI: 10.3233/JAD-2012-120787. View